APEIRON Biologics AG Revenue and Competitors
Employee Data
- APEIRON Biologics AG has 5 Employees.
- APEIRON Biologics AG grew their employee count by -44% last year.
APEIRON Biologics AG's People
Name | Title | Email/Phone |
---|
APEIRON Biologics AG Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 56 | 27% | N/A | N/A |
#2 | N/A | 12 | 33% | N/A | N/A |
#3 | N/A | 5 | -44% | N/A | N/A |
What Is APEIRON Biologics AG?
APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. \n\nOur company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.\n\nAPEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
keywords:N/AN/A
Total Funding
5
Number of Employees
N/A
Revenue (est)
-44%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 5 | 0% | N/A |
#2 | $0.8M | 6 | -25% | N/A |
#3 | $0.9M | 6 | 0% | N/A |
#4 | $0.8M | 6 | 50% | N/A |
#5 | $0.8M | 6 | -14% | N/A |